Introduction: We present a rare case of macrophage activation syndrome in apreviously well 53 year old male with apersistently unclear aetiology. Whilst the patient's response to anakinra has been consistent with underlying adult-onset Still's disease, the diagnostic criteria were not clearly met and a concomitant new diagnosis of ankylosing spondylitis raises the possibility of an unusual rheumatological trigger. Case description: A 53 year old male was referred to the infectious diseases team with a three-month history of pyrexia of unknown origin, together with intermittent sweating, rigors and dyspnoea on exertion. The patient had recently been treated successfully for chronic prostatitis with ciprofloxacin although it was felt that this did not entirely explain hissymptoms. Past medical history included hypertension but was otherwise unremarkable. Viral and bacterial serology, echocardiogram, plain chest films and lumbar puncture had no abnormal findings. An autoimmune screen was similarly negative and the patient was referred for wholebody FDG PET which showed no abnormal tracer uptake. The patient was subsequently reviewed by rheumatology and, on further questioning, reported stiffness of the back, neck and shoulders. On examination, there was reduced chest expansion, decreased cervical spinal flexion androtation andSchober'stest was positive at 3cm.MRIof the spinesubsequently revealed sacroiliitis and a diagnosis of ankylosing spondylitis was made. On outpatient review, the patient was found to be profoundly diaphoretic, tachypnoeic and tachycardic with a significantly elevated CRP. The patient reported worsening back pain, fevers and a swollen left knee together with an unwitnessed prior rash. The patient was admitted fromclinic and,following anincreaseinoxygenrequirements,wassubsequently transferred to ITU, where he was intubated. Whilst repeat serology and virology remained negative, plain chest x-ray revealed changes consistent with a rapidly-progressing ARDS and the patient was commenced on empirical antibiotic treatment for presumptive tuberculosis given the initial presentation. Over subsequent days, CRP remained significantly elevated over 300 despite antibiotics and aworsening thrombocytopaenia developed. Bone marrow and trephine biopsy revealed striking haemophagocytosis and the patient required full respiratory support together with cardiac inotropes and haemofiltration. The impression remained of a possible sepsis-driven systemic inflammatory response and multiple antimicrobial therapy continued. However, the patient remained refractory to treatment, including with etoposide, and a primary inflammatory process became more likely as an aetiology. Adult-onset Still's disease was raised as a differential given the possible history of fleeting arthritis and rash. In this context, the patient's haemophagocytic lymphohistiocytosis was thought to be macrophage-activation syndrome (MAS) and due to an underlying cytokine storm process. The lack of diagnostic certainty made the decision for immunosuppression difficult and the case was discussed with neurology, intensivists and infectious disease. The consensus was that sepsis of unknown source could not be excluded although, compounding this was the fact that the patient failed to respond to etoposide and high dose intravenous steroids. It was agreed to commence anakinra which was thought to be safe in the context of possible sepsis. The patient became afebrile twelve hours after subcutaneous administration and CRP reduced to 22 over subsequent days. The patient remained in ITU for a 76-day admission with multiorgan dysfunction and slow weaning necessitated an EEG which demonstrated periodic seizure activity. MRI brain confirmed multiple lesions with leptomeningeal enhancement and these were thought to be neurological sequelae of MAS. The patient was commenced on anticonvulsant medication. The patient continued to improve despite multiple pneumothoraces and a left subclavian deep vein thrombosis as a result of intervention. He also suffered from ITU-myopathy which required a period of physical rehabilitation but was discharged from hospital still on anakinra and on a weaning regimen of oral steroids. He has now been switched to methotrexate and remains clinically well. Discussion:This complex case clearly raises numerous interesting diagnostic challenges and uncertainties. The diagnosis of MAS crucially includes the histological finding of HLH on bone marrow biopsy which was present in this case. However, many of the other diagnostic features such as hepatosplenomegaly, hypofibrinogenaemia, multiple line cytopaenia and hyperferritinaemia were not found. MAS is most commonly secondary to juvenile idiopathic arthritis and, whilst evidence suggests it can be found with other rheumatological disease, there are very few cases to support ankylosing spondylitis as a cause. The patient did not convincingly fulfil a diagnosis of adult-onset Still's given a vague history of rash and persistently normal ferritin, although the presence of arthritis and ongoing pyrexia would obviously not entirely preclude this as an underlying cause, as would the striking clinical response to anakinra treatment. This case raises the rare possibility of ankylosing spondylitis driving a severe systemic inflammatory response but also questions what is known about the interplaybetween adult-onset Still's and MAS. Key Learning Points: The need for a multi-disciplinary approach with other specialties, especially infectious disease, when investing and treating complex patient with systemic inflammatory responses to fully exclude sepsis as a driving factor. To consider and explore all possible rheumatological conditions as a trigger for macrophage activation syndrome with the subsequent implications forpossible treatment options. Disclosure: J.S. Gill: None. S. Black: None. C. Raine: None. P. Mangat: None. ). X-rays of the hands, feet and chest were normal. She was diagnosed with a seronegative inflammatory arthritis and treated with sulfasalazine and prednisolone 7.5mg daily with good response. A year later she presented acutely with pleuritic chest pain, polyuria and weight loss. She was noted to have erythema nodosum and CT pulmonary angiogram excluded pulmonary embolus but demonstrated prominent mediastinal lymphadenopathy. Renal function was impaired (creatinine 141lmol/L) and serum ACE mildly raised (70). Calcium was normal (2.47mmol/L), urine dipstick negative for blood and protein, serum and urine protein electrophoresis negative and ultrasound of the renal tract normal. Diabetes mellitus was excluded with a normal fasting glucose (5.4) and HbA1c 41mmol/mol. A water deprivation test failed to concentrate urine nor improve with desmopressin indicating nephrogenic diabetes insipidus (DI). Subsequent renal biopsy demonstrated granulomatous tubulointerstitial nephritis, appearances consistent with sarcoid (image available but not able to upload to abstract submission). The patient was commenced on prednisolone 60mg daily and methotrexate with a rapid and marked improvement in symptoms and renal function (ESR 5mm/h, creatinine 93lmol/L and serum ACE 17). Discussion: Sarcoidosis may present with an inflammatory arthritis, and up to one third of patients are reported to have musculoskeletal involvement. Up to 40% of patients may have renal disease. Hypercalcemia is the most prevalent cause of renal dysfunction in sarcoidosis followed by granulomatous interstitial nephritis (GIN), tubular dysfunction, obstructive uropathy, granulomatous angiitis and rarely glomerular disease. The true incidence of renal involvement in sarcoid is unknown, as is progression to chronic kidney disease. Hypercalcaemia and hypercalciuria is the predominant cause of renal disease in sarcoid, and if left untreated will result in progressive tubulointerstitial inflammation, nephrocalcinosis and CKD. Granulomatous interstitial nephritis was identified in 7-23% of patients with sarcoidosis in an autopsy study, although many were clinically silent. Nephrogenic DI in the context of sarcoid is an extremely unusual presentation. There are only two previous published reports, one in the setting of pulmonary sarcoidosis with DI due to hypercalcaemia in 2003, and another case from 1965 (normocalcaemic). Proposed treatment pathways for GIN in sarcoid include glucocorticoids, followed by azathioprine or mycophenolate mofetil, with the final step including biologic treatments including infliximab (3 previous case reports of using infliximab with positive outcomes). Transplantation has been reported in renal sarcoidosis, however in a French series of 18 patients, 17% had recurrence of disease, but the long termeffect of this remains unknown. Key Learning Points: We have described a case of seronegative inflammatory arthritis which predated the onset of more classical features of systemic sarcoidosis presenting with erythema nodosum, mediastinal lymphadenopathy and granulomatous tubuloinsterstitial nephritis with nephrogenic diabetes insipidus. In the setting of sarcoidosis, cranial DI is more common than nephrogenic DI, but both should be considered in sarcoid patients presenting with polyuria and polydipsia. Granulomatous interstitial nephritis is not uncommon in sarcoid however other conditions which mimic GIN must be excluded, which include allergic reactions, chronic fungal or mycobacterial infections and neoplasia. Serum ACE levels are increased in many patients with chronic kidney disease or endstage renal disease of varying causes. The degree of elevation does not correlate with severity of the underlying renal failure. The majority of renal sarcoid is due to hypercalcaemia and hypercalciuria, and the true incidence of renal involvement in sarcoid is unknown as is the progression to CKD. Rheumatologists need to consider the renal manifestations of sarcoidosis when assessing these patients, particularly those with hypercalcemia, and should screen with 24 hour urinary calcium collections, renal ultrasound and considerreferral tonephrologists. Disclosure: K. Shah: None. S. Hamdulay: None. Introduction: Haemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory syndrome, characterised by the inappropriate survival of histiocytes and cytotoxic T-lymphocytes. HLH is underrecognised but should be suspected in the deteriorating, febrile patient and may present to any medical speciality. Delay in treatment leads rapidly to critical illness and death. Primary HLH results from a genetic defect which usually presents in infancy and is treated by stem cell transplant. Secondary HLH is classically triggered by autoimmune disease, particularly systemic juvenile idiopathic arthritis (sJIA) or systemic lupus eythematosis (SLE) when it is termed macrophage activation syndrome (MAS).
A THIRSTY PATIENT WITH PAINFUL JOINTS AND RENAL DYSFUNCTION

RHEUMATOLOGY AT THE INTERFACE OF MEDICINE: HAEMPHAGOCYTIC LYMPHOHISTIOCYTOSIS/MACROPHAGE
It isalso triggered by infection (particularly Epstein Barr virus and Varicella
Zoster) and malignancy (especially lymphoma). In adults mortality of HLH is 50-75% almost certainly because of late recognition and treatment. Diagnosis requires a high index of suspicion and interpretation of common investigations including full blood count (FBC), lipids, fibrinogen, liver function tests (LFT) and serum ferritin (often highly elevated >10,000 lg/L pathognomic of HLH/MAS in absence of iron overload). Bone marrow biopsy is not required for diagnosis. The H-score can be used to calculate the probability of secondary HLH and in the context of sJIA there are agreed diagnostic MAS criteria. Treatment of HLH involves aggressive immunosuppression, alongside management of the underlying trigger and recent guidance for recognition and treatment of adults with acquired HLH has been published. Due to lack of awareness of HLH among physicians diagnosis may be delayed or even missed leading to poor outcomes, highlighting a potential to improve identification and treatment of HLH and save lives as a result. Rheumatologists have a key part to play in recognition and treatment of HLH/MAS. We present four cases of HLH seen between 2014-2017 highlighting the clinical features, diagnosis and management strategies to promote the rheumatologygeneral medicine interface. Case description: Case 1: An HLH post-stem cell transplant 55-year-old man, usually fit and well, diagnosed with chronic myeloid leukaemia (CML) underwent allogenic stem cell transplant. Three months later presented with transaminitis, rash and diarrhoea and treated for graftversus-host disease (GvHD). Three months later, he was admitted with acute confusion, acute kidney injury (AKI) and pancytopenia, requiring intensive therapy unit (ITU) admission. He was treated presumptively for infection although no positive cultures were obtained. Eight months later he presented with fever and rigors and splenomegaly: a bone marrow biopsy showed reactive changes. There were no positive cultures from blood, CSF, urine, throat, skin or Hickmann line. Ferritin was 33 376lg/L, triglycerides 3.7mmol/L, fibrinogen 1.1g/L raising the suspicion of HLH. He was started on dexamethosone and ciclosporin A (CSA) which showed clinical improvement but intermittent pyrexia. He deteriorated twelve days later with type 1 respiratory failure and hypotension, requiring further ITU admission at which point his ferritin was > 100 000lg/L. He was then treated with intravenous (IV) methylprednisolone (MP) and IV Immunoglobulin (IVIg) and also rituximab, as EBV PCR was 54 700 copies/mL, the likely trigger for HLH. Ferritin started to fall but he had worsening AKI and persistent cytopenia so he was given Anakinra, in an attempt to terminate the cytokine storm. There was a swift improvement, and he was restarted on oral prednisolone and anakinra was withdrawn. He deteriorated again with confusion and pyrexia, requiring readmission to ITU. After initially repeating IVMP and IVIG, anakinra was reintroduced with good effect. He was eventually discharged on anakinra and despite CKD and persistently abnormal LFTs,he has remained well. Case 2: An HLH post varicella zoster infection 74-year-old man with bronchiectasis, but a high functional level, admitted with 10 days of fatigue, lethargy and intermittent confusion. Despite three days of treatment for pneumonia with IV tazocin he became more confused, developed abnormal liver function tests (LFTs) and remained febrile. Despite no positive cultures he was escalated to meropenem, but continued to spike temperatures and developed a pancytopenia, prompting a haematology review and bone marrow biopsy. He was resuscitated after cardiac arrest and taken to ITU. At this point, an ITU consultant queried HLH, with ferritin on 15 554lg/L despite no clear trigger. It then transpired he had shingles three weeks prior to admission and hadn't been quite right since. He was treated with IVMP and IVIG resulting in rapid resolution of pyrexia and normalisation of ferritin level and full blood count. After discharge from ITU, he made little communicative progress and a CT head demonstrated significant hypoxic brain injury from the cardiac arrest, making chance of recovery slim. He died aweek later following asecond cardiac arrest. Case 3: An HLH in sJIA 17-year-old man with sJIA and previous pericarditis, treated with methotrexate (MTX) and tocilizumab (TOC) was admitted with two days of fever and productive cough. He was treated for pneumonia but rapidly deteriorated prompting ITU admission and intubation. He had persistent pyrexia, worsening rash (attributed to his sJIA) and deteriorating LFTs. He had a generalised seizure and was admitted to a specialist neuro ITU. His ferritin was 24 814lg/L, with neutropenia, thombocytopenia and a bone marrow biopsy showing evidence of haemophagocytosis. An MRI brain demonstrated vasogenic oedema, consistent with posterior reversible encephalopathy syndrome (PRES), the aetiology of which presumed to be a combination of HLH and ciclosporin toxicity. He remained neutropenic but well, until deterioration with worsening generalised maculopapular rash. He was treated with IVMP, CSA (until he developed toxicity) and IVIG. Despite this he remained unwell and required etoposide, a powerful chemotherapeutic agent with antimacrophage effects. He made a complete recovery within a week and stabilised onTOC and MTX. Case 4: An HLH in SLE 39-year-old Chinese man, living in the UK for 10 years, with no past medical history admitted following a collapse. He also reported recent history of oral ulcers, joint pain, rash, night sweats, weight loss (10kg) and it was noted that he was confused, abbreviated mental test (AMT) 7/10. On examination he was febrile, and had cervical/axillary/ iliac lymphadenopathy. Urine dip showed blood and protein, with a urine protein creatinine ratio of 125. Further investigations showed a positive ANA, ENA, RNP, DsDNA and low complement, consistent with systemic lupus erythematosus (SLE). Six days post-admission, he had a rapid deterioration in consciousness with Glasgow coma scale (GCS) of six. Blood tests showed worsening liver function, ferritin 52 000lg/L and raised triglycerides. He was treated for HLH with IVMP and IVIG, resulting in rapid resolution of pyrexia, return to GCS of 15 and progressive improvement in rash, joint pain and proteinuria. He remained stable on a reducing wean of oral prednisolone along with introduction of mycofenylate mofetil (MMF) and hydroxychlorquine (HCQ). Discussion: Secondary HLH is under-recognised in adolescent and adult patients and should be considered in both the rheumatology and general medical population. New guidance suggests that early treatment with immunosuppression (initially methylprednisolone þ/-IVIG and early consideration of anakinra) is both safe and effective in the critically unwell patient so raising awareness of HLH is key. Clinicians need to have a high index of suspicion and in particular should think of HLH in patients with fever, confusion, hepatosplenomegaly, dual or pan-lineage cytopenia and multi-organ failure. Serum markers ferritin, triglycerides, fibrinogen and LFTs can be used alongside the clinical features to guide diagnosis. The H-score, a free online calculator, is a validated tool, into which these parameters are inputted to give a probability of HLH. The two rheumatology cases here demonstrate that rheumatologists are aware of HLH and treat early with good outcome. We have presented two general medical cases also with relatively good outcome reflecting the HLH network set up in our Trust resulting in both patients having early recognition of HLH by their non-rheumatology parent teams and early, combined intervention. We recognize that HLH generally and particularly that presenting as a result of lymphoma or other malignancy has a poor outcome. Our HLH network would suggest that HLH is not rare; between 2014 and 2018 we have been involved in managing around 30 cases. Better awareness of HLH in rheumatology and beyondwill improve patient care Key Learning Points: The febrile, thrombocytopaenic and unwell/deteriorating with no identified pathogen or disease should mandate estimation of serum ferritin and consideration of HLH. Screen these patients using serum ferritin, and stratify their risk of HLH using the H score Early treatment involving IVMP, IVIG, CSA and Anakinra can help to abort the cytokine storm, but the underlying trigger, such as EBV infection, malignancy or autoimmune disease must be treated concurrently.
